Endometrial cancer
Conditions
Interventions
None listed
Sponsors
JGOG
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed histologically or clinically with uterine body cancer (including carcinosarcoma) 2) Patients who have provided written consent for participation in this study 3) Patients who were 18 years of age or older at the time of consent acquisition 4) Patients who underwent postoperative chemotherapy including platinum agents 5) Patients who are planned to receive treatment with combination therapy of TKI+ICI, platinum agent combination therapy (up to 2 agents), or regimens including ICI as primary treatment after disease progression or recurrence following postoperative chemotherapy 6) Patients with measurable lesions by CT or MRI imaging at the time of disease progression or recurrence.
Exclusion criteria
Exclusion criteria: 1) Patients deemed inappropriate as study subjects by the principal investigator and co-investigators 2) Patients who underwent radiation therapy or chemoradiotherapy after surgery (including external radiation therapy and brachytherapy, but palliative radiation therapy for pain relief to bones, brain, or other sites is allowed) 3) Patients who received preoperative treatment 4) Patients who underwent drug therapy with regimens other than cohorts A-C 5) Patients with concomitant active multiple cancers 6) Patients who are participating in clinical research involving interventions (including clinical trials) at the time of case registration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The implementation rates of each drug therapy regimen in actual clinical practice and the progression-free survival periods by cohort for primary treatment after disease progression or recurrence following postoperative chemotherapy. | — |
Countries
Japan
Contacts
Public ContactSeiichiro Takahashi
JGOG JGOG Office
Outcome results
None listed